0138 GMT - Healius's share price drops 22% to an all-time low of A$0.38 after the Australian healthcare company warned on profits. Healius now expects underlying Ebitda of A$259 million-A$264 million in FY 2026. That's well below RBC's A$277 million forecast ahead of today's update. Analyst Craig Wong-Pan says the update implies Healius's pathology volumes deteriorated from 1.2% growth in 1H to a 2.8% decline in the four months through April, while pathology revenue growth fell to 0.7% in 2H so far, from 3.5% in 1H. "We believe Healius has lost share in the 2H period given Medicare pathology volume and benefits paid growth for the three months to March were 1.9% and 1.6% respectively," RBC says. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

May 12, 2026 21:38 ET (01:38 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.